Pipeline

GQ-201 is a gene therapy product candidate for the treatment of osteoarthritis in horses. The product candidates GQ-202 and GQ-203 are the respective analogues for osteoarthritis in dogs and humans. In December 2017, GQ-203 was acquired by Flexion Therapeutics, Inc. and is now called FX201.

GeneQuine is also developing the gene therapy product candidates GQ-301, GQ-302 and GQ-303 for osteoarthritis in horses, dogs and humans, respectively. Compared to the 200 series, these product candidates express a protein with a different pharmacological profile and mechanism of action.

Human product candidates:

Preclinical Studies Clinical
Phase I
Clinical
Phase II
Clinical
Phase III
Market Authorization
GQ-203/FX201 Sold to Flexion Therapeutics, Inc.
GQ-303

Veterinary product candidates:

Experimental Studies Proof-of-Concept in Target Species Toxicology, Pharmacokinetics, Pharmacodynamics Clinical Field Studies Market Authorization
GQ-201
(Horses)
GQ-202
(Dogs)
GQ-301
(Horses)
GQ-302
(Dogs)